Regorafenib Alone or in Combined With Transcatheter Arterial ChEmoembolization in Treatment of Advanced Hepatocellular Carcinoma After First Line Targeted Therapy

Launched by WENBO GUO · Apr 12, 2023

Keywords

ClinConnect Summary

This clinical trial is exploring how well a medication called regorafenib works alone or when combined with a procedure called Transcatheter Arterial Chemoembolization (TACE) for treating advanced liver cancer, specifically hepatocellular carcinoma (HCC), in patients who have not responded to earlier treatments. The main goals of the study are to compare the effectiveness of these two treatment approaches, assess how safe regorafenib is for patients, and see if adding TACE improves outcomes for patients receiving second-line treatment for their cancer.

To participate in this trial, individuals must be between 18 to 75 years old and have been diagnosed with advanced liver cancer that has come back after initial treatment. They should also have at least one measurable tumor in the liver and a certain level of liver function. Participants will receive treatment and be closely monitored for their response and any side effects. It’s important to note that individuals with certain other types of liver cancer, recent other cancers, or serious health issues may not qualify for this study. If you or a loved one is considering participation, this trial could provide access to potentially beneficial treatments for advanced liver cancer.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • ( - ) After pathological / clinical diagnosis of hepatocellular carcinoma or radical resection of hepatocellular carcinoma; ( - ) CNLC Ⅲa Patients with intrahepatic recurrence before (including a); ( - ) Previous failure of first-line systemic treatment; ( - ) Age: 18-75 years old; ( - ) Child-Pugh 7 points; ( - ) ECOG PS Grade 0-2; ( - ) At least one measurable lesion in the liver.
• Exclusion Criteria:
• • ( - ) Known hepatobiliary tubular cell carcinoma and mixed cell carcinoma and fibrolamellar cell carcinoma; ( - ) Previous (within 5 years) or concurrent other incurable malignant tumors; ( - ) Having received local treatment, systemic chemotherapy, radiotherapy other than TACE during the first-line systemic treatment; ( - ) During the second-line systemic treatment, I also received local treatment, systemic chemotherapy, radiotherapy other than TACE; ( - ) Serious uncontrollable systemic and other systemic diseases, such as uremia, cardiovascular and cerebrovascular accidents; ( - ) Allergy to any drug included in the study; ( - ) Pregnant or lactating women;